NeOnc Reports Early Improvement in Child Receiving NEO100 Under Compassionate Use
Bitget2026/10/16 12:03- NeOnc Technologies reported early clinical improvement in its first child treated with investigational NEO100 under compassionate use in Abu Dhabi.
- The three-year-old boy with an aggressive brain tumor is breathing without ventilator support, according to treating physicians.
- Physicians also reported emerging leg movement following treatment with the intranasal drug.
- Treatment occurred outside the NEO100-03 pediatric trial because the child did not meet eligibility criteria.
- The single-patient observations do not establish that NEO100 caused improvement; pediatric safety and efficacy remain unproven.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Is AI an engine or a killer? Morgan Stanley provides answers with data: productivity soars, but nearly 90% of the benefits are taken by 12 industries
Morgan Stanley stated that the productivity dividends from AI are concentrated in 12 highly exposed industries, with growth rates reaching twice the twenty-year average. For the first time, signs of job replacement have emerged.
Production Increase Falls Short, Layoffs First! Boeing (BA.US) Cuts 5% of Commercial Airplane Jobs, Delays 737 Monthly Production Target of 47 Aircraft to 2027
Stephanie Pope, head of Boeing's commercial airplanes division, informed employees in an internal memo on Monday that due to obstacles in increasing aircraft production, the division plans to cut 5% of its workforce.
Crypto prices
More
